Montes de Jesus F, Dierickx D, Vergote V, Noordzij W, Dierckx R A J O, Deroose C M, Glaudemans A W J M, Gheysens O, Kwee T C
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
EJNMMI Res. 2021 Mar 18;11(1):29. doi: 10.1186/s13550-021-00769-8.
Post-transplant lymphoproliferative disorders (PTLDs) are a spectrum of hematological malignancies occurring after solid organ and hematopoietic stem cell transplantation. [F]FDG PET/CT is routinely performed at PTLD diagnosis, allowing for both staging of the disease and quantification of volumetric parameters, such as whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG). In this retrospective study, we aimed to determine the prognostic value of MTV and TLG in PTLD patients, together with other variables of interest, such as the International Prognostic Index (IPI), organ transplant type, EBV tumor status, time after transplant, albumin levels and PTLD morphology.
A total of 88 patients were included. The 1-, 3-, 5- year overall survival rates were 67%, 58% and 43% respectively. Multivariable analysis indicated that a high IPI (HR: 1.56, 95% CI: 1.13-2.16) and an EBV-negative tumor (HR: 2.71, 95% CI: 1.38-5.32) were associated with poor overall survival. Patients with a kidney transplant had a longer overall survival than any other organ recipients (HR: 0.38 95% CI: 0.16-0.89). IPI was found to be the best predicting parameter of overall survival in our cohort. Whole-body MTV, TLG, time after transplant, hypoalbuminemia and PTLD morphology were not associated with overall survival.
[F]FDG PET/CT whole-body volumetric quantitative parameters were not predictive of overall survival in PTLD. In our cohort, high IPI and an EBV-negative tumor were found to predictors of worse overall survival while kidney transplant patients had a longer overall survival compared to other organ transplant recipients.
移植后淋巴细胞增殖性疾病(PTLD)是实体器官和造血干细胞移植后发生的一系列血液系统恶性肿瘤。[F]FDG PET/CT在PTLD诊断时常规进行,可用于疾病分期以及量化体积参数,如全身代谢肿瘤体积(MTV)和总病变糖酵解(TLG)。在这项回顾性研究中,我们旨在确定MTV和TLG在PTLD患者中的预后价值,以及其他相关变量,如国际预后指数(IPI)、器官移植类型、EBV肿瘤状态、移植后时间、白蛋白水平和PTLD形态。
共纳入88例患者。1年、3年、5年总生存率分别为67%、58%和43%。多变量分析表明,高IPI(HR:1.56,95%CI:1.13 - 2.16)和EBV阴性肿瘤(HR:2.71,95%CI:1.38 - 5.32)与总生存不良相关。肾移植患者的总生存期比其他器官移植受者更长(HR:0.38,95%CI:0.16 - 0.89)。在我们的队列中,IPI被发现是总生存的最佳预测参数。全身MTV、TLG、移植后时间、低白蛋白血症和PTLD形态与总生存无关。
[F]FDG PET/CT全身体积定量参数不能预测PTLD的总生存。在我们的队列中,高IPI和EBV阴性肿瘤是总生存较差的预测因素,而肾移植患者与其他器官移植受者相比总生存期更长。